Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2019.101891
Abstract: Collecting ducts carcinoma (CDC) is a rare and aggressive histological subtype of renal cancer accounting for only 1% of renal tumors. Usually patients present in bad clinical conditions due to a symptomatic disease with synchronous… read more here.
Keywords: literature; treatment; disease; ducts carcinoma ... See more keywords
A phase 2 prospective trial of cabozantinib as first-line treatment for metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2) clinical trial information—NCT03354884.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.4571
Abstract: 4571 Background: Metastatic collecting ducts carcinoma (mCDC) is a rare disease with bad prognosis and no standard treatments. Due to its rarity, mCDC is biologically poorly characterized and under-represented in prospective randomized trials. We recently… read more here.
Keywords: clinical trial; trial; treatment; trial information ... See more keywords
Transcription factor TFCP2L1 patterns cells in the mouse kidney collecting ducts
Sign Up to like & getrecommendations! Published in 2017 at "eLife"
DOI: 10.7554/elife.24265
Abstract: Although most nephron segments contain one type of epithelial cell, the collecting ducts consists of at least two: intercalated (IC) and principal (PC) cells, which regulate acid-base and salt-water homeostasis, respectively. In adult kidneys, these… read more here.
Keywords: factor tfcp2l1; cell; transcription factor; tfcp2l1 ... See more keywords